KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Debt (2016 - 2025)

Emergent BioSolutions' Non-Current Debt history spans 16 years, with the latest figure at $572.1 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 13.8% year-over-year to $572.1 million; the TTM value through Dec 2025 reached $572.1 million, down 13.8%, while the annual FY2025 figure was $572.1 million, 13.8% down from the prior year.
  • Non-Current Debt reached $572.1 million in Q4 2025 per EBS's latest filing, down from $663.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $1.0 billion in Q3 2022 to a low of $446.5 million in Q4 2023.
  • Average Non-Current Debt over 5 years is $646.9 million, with a median of $663.4 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: tumbled 56.57% in 2023, then soared 49.4% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $809.4 million in 2021, then crashed by 44.59% to $448.5 million in 2022, then decreased by 0.45% to $446.5 million in 2023, then soared by 48.65% to $663.7 million in 2024, then decreased by 13.8% to $572.1 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Non-Current Debt are $572.1 million (Q4 2025), $663.1 million (Q3 2025), and $667.8 million (Q2 2025).